{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:26:05Z","timestamp":1787304365172,"version":"build-2736575974"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Blood-based biomarkers (BBMs) are increasingly being integrated into Alzheimer\u2019s disease (AD) clinical pathways by providing scalable tools to track amyloid, tau, neurodegeneration, and inflammation dimensions of the ATN-I framework. As biological characterization and biomarker-informed assessment are increasingly integrated into AD care, there is growing interest in clinically applicable blood-based approaches capable of reflecting AD-related biological changes across different disease stages. This review examines recent advances in BBMs through the ATN-I framework while emphasizing their clinical decision value, analytical feasibility, economic considerations, and implementation barriers across different healthcare settings. Building on these findings, we examine the evidence supporting clinical use, with a focus on appropriate use criteria, clinical validation, laboratory feasibility, and consistent interpretation methods. Furthermore, this review explores how integrating BBMs with traditional cerebrospinal fluid and neuroimaging tests may support symptom-driven clinical triage, probability refinement, and early evaluation in selected individuals, improving clinical workflow efficiency and accessibility. Finally, the article addresses remaining challenges related to clinical validation, platform accessibility, cost-effectiveness, and equitable deployment, highlighting how emerging biomarker strategies may contribute to more scalable AD assessment.<\/jats:p>","DOI":"10.3389\/fnagi.2026.1852137","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:47:16Z","timestamp":1787302036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Translating blood-based biomarkers into Alzheimer\u2019s disease clinical practice: screening, diagnosis, and longitudinal monitoring"],"prefix":"10.3389","volume":"18","author":[{"given":"Binbin","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Neurology, Chongqing Mental Health Center","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Chongqing Mental Health Center","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hospital-Acquired Infection Control, Chongqing Mental Health Center","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chongqing Mental Health Center","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"You","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chongqing Mental Health Center","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chongqing Mental Health Center","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100205","DOI":"10.1016\/j.tjpad.2025.100205","article-title":"Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer\u2019s disease.","volume":"12","author":"Abbas","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders.","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e14621","DOI":"10.1002\/alz.14621","article-title":"Biomarker discovery in Alzheimer\u2019s and neurodegenerative diseases using nucleic acid linked immuno-sandwich assay.","volume":"21","author":"Ashton","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light.","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring.","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12882-025-04130-2","article-title":"Plasma concentrations of neurofilament light, p-Tau231 and glial fibrillary acidic protein are elevated in patients with chronic kidney disease and correlate with measured glomerular filtration rate.","volume":"26","author":"Axelsson","year":"2025","journal-title":"BMC Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41531-025-00951-y","article-title":"Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism.","volume":"11","author":"Baiardi","year":"2025","journal-title":"NPJ Parkinsons Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13195-024-01391-1","article-title":"Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.","volume":"16","author":"Bali","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests.","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.tjpad.2025.100224","article-title":"Impact of cardiovascular risk factors on plasma biomarkers in prediction of Alzheimer\u2019s and cerebrovascular neuropathology.","volume":"12","author":"Bermudez","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e12321","DOI":"10.1002\/dad2.12321","article-title":"Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology.","volume":"14","author":"Berry","year":"2022","journal-title":"Alzheimers Dement."},{"key":"B13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework.","volume":"69","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e14414","DOI":"10.1002\/alz.14414","article-title":"Biomarker treatment effects in two phase 3 trials of gantenerumab.","volume":"21","author":"Bittner","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/bf02815140","article-title":"Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?","volume":"26","author":"Blennow","year":"1995","journal-title":"Mol. Chem. Neuropathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cca.2022.08.017","article-title":"Plasma neurofilament light chain (NfL) reference interval determination in an Age-stratified cognitively unimpaired cohort.","volume":"535","author":"Bornhorst","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e210287","DOI":"10.1212\/wnl.0000000000210287","article-title":"Quantitative assessment of the effect of chronic kidney disease on plasma P-Tau217 concentrations.","volume":"104","author":"Bornhorst","year":"2025","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.14336\/ad.2023.1226","article-title":"Association of plasma markers of Alzheimer\u2019s disease, neurodegeneration, and neuroinflammation with the choroid plexus integrity in aging.","volume":"15","author":"Bouhrara","year":"2024","journal-title":"Aging Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1001\/jamaneurol.2025.0142","article-title":"Cognitive phenotyping and interpretation of alzheimer blood biomarkers.","volume":"82","author":"Bouteloup","year":"2025","journal-title":"JAMA Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study.","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement."},{"key":"B21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/acn3.51529","article-title":"Correlation of plasma and neuroimaging biomarkers in Alzheimer\u2019s disease.","volume":"9","author":"Brickman","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2545046","DOI":"10.1001\/jamanetworkopen.2025.45046","article-title":"Alzheimer disease blood biomarker concentrations across race and ethnicity groups in middle-aged adults.","volume":"8","author":"Brickman","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases.","volume":"3","author":"Brum","year":"2023","journal-title":"Nat. Aging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/s41467-024-46603-2","article-title":"A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings.","volume":"15","author":"Brum","year":"2024","journal-title":"Nat. Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13195-023-01296-5","article-title":"Performance of plasma A\u03b242\/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status.","volume":"15","author":"Bun","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1038\/s41467-023-42596-6","article-title":"Plasma biomarkers predict Alzheimer\u2019s disease before clinical onset in Chinese cohorts.","volume":"14","author":"Cai","year":"2023","journal-title":"Nat. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/jad-190533","article-title":"Ultrasensitive detection of plasma amyloid-\u03b2 as a biomarker for cognitively normal elderly individuals at risk of Alzheimer\u2019s disease.","volume":"71","author":"Chatterjee","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimers Dement."},{"key":"B29","doi-asserted-by":"publisher","first-page":"100160","DOI":"10.1016\/j.tjpad.2025.100160","article-title":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer\u2019s disease.","volume":"12","author":"Chen","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13195-023-01246-1","article-title":"Reference intervals for plasma amyloid-\u03b2, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment.","volume":"15","author":"Chen","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e70750","DOI":"10.1002\/alz.70750","article-title":"Lecanemab treatment for Alzheimer\u2019s Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China.","volume":"21","author":"Chen","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B32","doi-asserted-by":"publisher","first-page":"101446","DOI":"10.1016\/j.arr.2021.101446","article-title":"Diagnostic accuracy of blood biomarkers for Alzheimer\u2019s disease and amnestic mild cognitive impairment: A meta-analysis.","volume":"71","author":"Chen","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13195-025-01892-7","article-title":"Prognostic value of plasma biomarkers in early Alzheimer\u2019s disease: A longitudinal clinical and neuroimaging study.","volume":"17","author":"Clemmensen","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e14629","DOI":"10.1002\/alz.14629","article-title":"Plasma Alzheimer\u2019s disease biomarker relationships with incident abnormal amyloid PET.","volume":"21","author":"Cogswell","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B35","doi-asserted-by":"publisher","first-page":"fcae247","DOI":"10.1093\/braincomms\/fcae247","article-title":"Multi-peptide characterization of plasma neurofilament light chain in preclinical and mild Alzheimer\u2019s disease.","volume":"6","author":"Coulton","year":"2024","journal-title":"Brain Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e70098","DOI":"10.1002\/trc2.70098","article-title":"Alzheimer\u2019s disease drug development pipeline: 2025.","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.17219\/acem\/208917","article-title":"Blood biomarkers of Alzheimer\u2019s disease: Balancing clinical relevance with improved accessibility and sustainability.","volume":"34","author":"Daly","year":"2025","journal-title":"Adv. Clin. Exp. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/arclin\/acae019","article-title":"Plasma biomarkers for Alzheimer\u2019s and related dementias: A review and outlook for clinical neuropsychology.","volume":"39","author":"Dark","year":"2024","journal-title":"Arch. Clin. Neuropsychol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13195-020-00728-w","article-title":"Comparison of ELISA- and SIMOA-based quantification of plasma A\u03b2 ratios for early detection of cerebral amyloidosis.","volume":"12","author":"De Meyer","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1002\/alz.14100","article-title":"Longitudinal plasma phosphorylated-tau217 and other related biomarkers in a non-demented Alzheimer\u2019s risk-enhanced sample.","volume":"20","author":"Du","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e214220","DOI":"10.1212\/wnl.0000000000214220","article-title":"Alzheimer disease, vascular disease, and blood-brain barrier permeability biomarkers in middle-aged adults.","volume":"105","author":"Edwards","year":"2025","journal-title":"Neurology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e14203","DOI":"10.1002\/alz.14203","article-title":"Paving the way for Alzheimer\u2019s disease blood-based biomarkers in primary care.","volume":"21","author":"Erickson","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1320653","DOI":"10.3389\/fneur.2024.1320653","article-title":"Evaluation of serum neurofilament light chain and glial fibrillary acidic protein in the diagnosis of Alzheimer\u2019s disease.","volume":"15","author":"Fang","year":"2024","journal-title":"Front. Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium.","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1515\/cclm-2023-1256","article-title":"Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays.","volume":"62","author":"Fazeli","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e214441","DOI":"10.1212\/wnl.0000000000214441","article-title":"Evaluating Plasma p-tau217 as an endpoint for Alzheimer disease clinical trials.","volume":"106","author":"Ferreira","year":"2026","journal-title":"Neurology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1212\/wnl.0000000000207115","article-title":"Potential utility of plasma P-Tau and neurofilament light chain as surrogate biomarkers for preventive clinical trials.","volume":"101","author":"Ferreira","year":"2023","journal-title":"Neurology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1002\/alz.14140","article-title":"Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays.","volume":"20","author":"Figdore","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B49","doi-asserted-by":"publisher","first-page":"8198","DOI":"10.1002\/alz.14263","article-title":"Current status of professional memory clinics, inpatient services, and health professionals in China.","volume":"20","author":"Gan","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.scib.2023.07.009","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: A multicenter-based cross-sectional and longitudinal study in China.","volume":"68","author":"Gao","year":"2023","journal-title":"Sci. Bull."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/s2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019.","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e70116","DOI":"10.1002\/dad2.70116","article-title":"The two cut-offs approach for plasma p-tau217 in detecting Alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment.","volume":"17","author":"Giacomucci","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2022.07.006","article-title":"Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer\u2019s disease.","volume":"119","author":"Graff-Radford","year":"2022","journal-title":"Neurobiol. Aging"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e14367","DOI":"10.1002\/alz.14367","article-title":"Generalizability of tau and amyloid plasma biomarkers in Alzheimer\u2019s disease cohorts of diverse genetic ancestries.","volume":"21","author":"Griswold","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B55","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases.","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease.","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e70113","DOI":"10.1002\/alz.70113","article-title":"Cut-points and gray zones: The challenges of integrating Alzheimer\u2019s disease plasma biomarkers into clinical practice.","volume":"21","author":"Hazan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B58","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-024-02068-7","article-title":"Analysis of cerebrospinal fluid, plasma \u03b2-amyloid biomarkers, and cognition from a 2-year phase 2 trial evaluating oral ALZ-801\/valiltramiprosate in APOE4 carriers with Early Alzheimer\u2019s disease using quantitative systems pharmacology model.","volume":"84","author":"Hey","year":"2024","journal-title":"Drugs"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9982","DOI":"10.1038\/s41467-024-52937-8","article-title":"Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer\u2019s disease.","volume":"15","author":"Hofmann","year":"2024","journal-title":"Nat. Commun."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease.","volume":"31","author":"Horie","year":"2025","journal-title":"Nat. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5582\/ddt.2025.01055","article-title":"The pTau217\/A\u03b2(1-42) plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer\u2019s disease.","volume":"19","author":"Hu","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/wnl.0000000000011226","article-title":"Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease.","volume":"96","author":"Ill\u00e1n-Gala","year":"2021","journal-title":"Neurology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1002\/alz.13084","article-title":"Plasma ATN(I) classification and precision pharmacology in Alzheimer\u2019s disease.","volume":"19","author":"Imbimbo","year":"2023","journal-title":"Alzheimers Dement."},{"key":"B64","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/jamaneurol.2025.2974","article-title":"Concurrent changes in plasma phosphorylated Tau 217, Tau PET, and cognition in preclinical Alzheimer disease.","volume":"82","author":"Insel","year":"2025","journal-title":"JAMA Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup.","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B66","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-Tau assays in prodromal Alzheimer\u2019s disease.","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"B68","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","article-title":"Plasma phosphorylated Tau 217 and A\u03b242\/40 to predict early brain A\u03b2 accumulation in people without cognitive impairment.","volume":"81","author":"Janelidze","year":"2024","journal-title":"JAMA Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8 plasma Amyloid-\u03b2 42\/40 assays in Alzheimer disease.","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","article-title":"Biomarker changes during 20 years preceding Alzheimer\u2019s disease.","volume":"390","author":"Jia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e70194","DOI":"10.1002\/dad2.70194","article-title":"Establishment and verification of reference intervals for Alzheimer\u2019s disease plasma biomarkers based on evaluation of pre-analytical procedures: a multicenter study.","volume":"17","author":"Jiang","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-025-01712-y","article-title":"Evaluating the diagnostic performance of six plasma biomarkers for Alzheimer\u2019s disease and other neurodegenerative dementias in a large Chinese cohort.","volume":"17","author":"Jiao","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13195-026-02119-z","article-title":"Age-dependent diagnostic and correlational architecture of multiplex plasma biomarkers in Alzheimer\u2019s disease: A cross-ethnic, cross-platform validation study.","volume":"18","author":"Jin","year":"2026","journal-title":"Alzheimers Res. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/brain\/awac399","article-title":"Plasma biomarker profiles in autosomal dominant Alzheimer\u2019s disease.","volume":"146","author":"Johansson","year":"2023","journal-title":"Brain"},{"key":"B75","doi-asserted-by":"publisher","first-page":"91","DOI":"10.12779\/dnd.2025.24.2.91","article-title":"Reproducibility of plasma biomarker measurements across laboratories: Insights into ptau217, GFAP, and NfL.","volume":"24","author":"Kang","year":"","journal-title":"Dement. Neurocogn. Disord."},{"key":"B76","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13195-025-01826-3","article-title":"Plasma phosphorylated tau 217 and amyloid-\u03b2 42\/40 for amyloid risk in subgroups.","volume":"17","author":"Kang","year":"","journal-title":"Alzheimers Res. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-3-030-32633-3_19","article-title":"Exosome biomarkers revolutionize preclinical diagnosis of neurodegenerative diseases and assessment of treatment responses in clinical trials.","volume":"1195","author":"Kapogiannis","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/brain\/awaa403","article-title":"Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70.","volume":"144","author":"Keshavan","year":"2021","journal-title":"Brain"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e70319","DOI":"10.1002\/alz.70319","article-title":"Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity.","volume":"21","author":"Kirsebom","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B80","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1176\/appi.focus.20170048","article-title":"Biomarkers in Alzheimer\u2019s, frontotemporal, lewy body, and vascular dementias.","volume":"16","author":"Koenig","year":"2018","journal-title":"Focus"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e70263","DOI":"10.1002\/dad2.70263","article-title":"Population disparities in Alzheimer\u2019s disease: A systematic review of fluid and neuroimaging biomarkers.","volume":"18","author":"Kpelle","year":"2026","journal-title":"Alzheimers Dement."},{"key":"B82","doi-asserted-by":"publisher","first-page":"100572","DOI":"10.1016\/j.tjpad.2026.100572","article-title":"Cost analyses of plasma p-tau217 versus p-tau217\/A\u03b242 ratio using two-step approach in the Japanese health care system.","volume":"13","author":"Kurihara","year":"2026","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/s43587-025-00904-3","article-title":"Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer\u2019s disease in a multicenter and multiethnic aging population.","volume":"5","author":"Lan","year":"2025","journal-title":"Nat. Aging"},{"key":"B84","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1186\/s12913-026-14405-5","article-title":"Cost-utility analysis of cerebrospinal fluid versus blood biomarkers for early detection of Alzheimer\u2019s disease and mild cognitive impairment in Thailand: A modeling study.","volume":"26","author":"Leelahavarong","year":"2026","journal-title":"BMC Health Serv. Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease.","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.26891","article-title":"Timing of biomarker changes in sporadic Alzheimer\u2019s disease in estimated years from symptom onset.","volume":"95","author":"Li","year":"2024","journal-title":"Ann. Neurol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1002\/alz.14091","article-title":"Cardiometabolic multimorbidity, peripheral biomarkers, and dementia in rural older adults: The MIND-China study.","volume":"20","author":"Liu","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1599761","DOI":"10.3389\/fnagi.2025.1599761","article-title":"A high-accuracy, low-cost blood test for Alzheimer\u2019s disease: Validating P-tau181\/A\u03b242 in real-world cohorts.","volume":"17","author":"Liu","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e0234519","DOI":"10.1371\/journal.pone.0234519","article-title":"Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology.","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"B90","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41398-026-04050-1","article-title":"Correlation between peripheral and central inflammatory and neuronal injury markers in mild cognitive impairment patients: The role of blood-brain barrier status.","volume":"16","author":"Liu","year":"2026","journal-title":"Transl. Psychiatry"},{"key":"B91","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fnagi.2017.00226","article-title":"Plasma levels of A\u03b242 and Tau identified probable Alzheimer\u2019s dementia: Findings in two cohorts.","volume":"9","author":"Lue","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"101561","DOI":"10.1016\/j.lanwpc.2025.101561","article-title":"Evolution of strategic framework of policies related to dementia care and prevention in China from 2000 to 2024.","volume":"58","author":"Luo","year":"2025","journal-title":"Lancet Reg. Health West Pac."},{"key":"B93","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-025-01719-5","article-title":"Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform.","volume":"17","author":"Mart\u00ednez-Dubarbie","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13195-024-01642-1","article-title":"Longitudinal trajectory of plasma p-tau217 in cognitively unimpaired subjects.","volume":"16","author":"Mart\u00ednez-Dubarbie","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"100219","DOI":"10.1016\/j.tjpad.2025.100219","article-title":"Estimation of the value-based price of a blood test for Alzheimer\u2019s disease pathology in primary and specialty care in the U.S.","volume":"12","author":"Mattke","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"5596","DOI":"10.1002\/alz.13348","article-title":"Preparedness of China\u2019s health care system to provide access to a disease-modifying Alzheimer\u2019s treatment.","volume":"19","author":"Mattke","year":"2023","journal-title":"Alzheimers Dement."},{"key":"B97","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies.","volume":"81","author":"Mattsson-Carlgren","year":"2024","journal-title":"JAMA Neurol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of Longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers.","volume":"80","author":"Mattsson-Carlgren","year":"2023","journal-title":"JAMA Neurol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"8209","DOI":"10.1002\/alz.14150","article-title":"Considerations for widespread implementation of blood-based biomarkers of Alzheimer\u2019s disease.","volume":"20","author":"Mielke","year":"","journal-title":"Alzheimers Dement."},{"key":"B101","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease.","volume":"20","author":"Mielke","year":"","journal-title":"Alzheimers Dement."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e2458149","DOI":"10.1001\/jamanetworkopen.2024.58149","article-title":"Alzheimer disease blood biomarkers and cognition among individuals with diabetes and overweight or obesity.","volume":"8","author":"Mielke","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B103","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","article-title":"Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and Tau pathologies.","volume":"3","author":"Montoliu-Gaya","year":"2023","journal-title":"Nat. Aging"},{"key":"B104","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis.","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s43587-025-00835-z","article-title":"Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials.","volume":"5","author":"Ossenkoppele","year":"2025","journal-title":"Nat. Aging"},{"key":"B106","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/s1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: Towards implementation in clinical practice and trials.","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e70828","DOI":"10.1002\/alz.70828","article-title":"Blood-based biomarkers for detecting Alzheimer\u2019s disease pathology in cognitively impaired individuals within specialized care settings: A systematic review and meta-analysis.","volume":"21","author":"Pahlke","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B109","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/adr-230029","article-title":"Plasma biomarkers of Alzheimer\u2019s disease: A review of available assays, recent developments, and implications for clinical practice.","volume":"7","author":"Pais","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care.","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","article-title":"Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform.","volume":"31","author":"Palmqvist","year":"","journal-title":"Nat. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"e70535","DOI":"10.1002\/alz.70535","article-title":"Alzheimer\u2019s association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings.","volume":"21","author":"Palmqvist","year":"","journal-title":"Alzheimers Dement."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e70987","DOI":"10.1002\/alz.70987","article-title":"Plasma P-tau217, GFAP, and NfL as biomarkers for Alzheimer\u2019s disease: Role in disease stratification, pathological progression, and cognitive decline.","volume":"21","author":"Pan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-024-01655-w","article-title":"Plasma phospho-tau217 as a predictive biomarker for Alzheimer\u2019s disease in a large south American cohort.","volume":"17","author":"Pandey","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"165","DOI":"10.12779\/dnd.2024.23.4.165","article-title":"Lecanemab: Appropriate use recommendations by Korean dementia association.","volume":"23","author":"Park","year":"2024","journal-title":"Dement. Neurocogn. Disord."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-022-01143-z","article-title":"Clinical performance of an antibody-free assay for plasma A\u03b242\/A\u03b240 to detect early alterations of Alzheimer\u2019s disease in individuals with subjective cognitive decline.","volume":"15","author":"Pascual-Lucas","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/alz.13450","article-title":"Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer\u2019s disease progression.","volume":"20","author":"Pelkmans","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/alz.12801","article-title":"Clinical performance and robustness evaluation of plasma amyloid-\u03b2(42\/40) prescreening.","volume":"19","author":"Rabe","year":"2023","journal-title":"Alzheimers Dement."},{"key":"B119","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13195-025-01727-5","article-title":"Clinical phenotypes of Alzheimer\u2019s disease: Investigating atrophy patterns and their pathological correlates.","volume":"17","author":"Reijner","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3233\/jad-210391","article-title":"Plasma amyloid and in vivo brain amyloid in late middle-aged hispanics.","volume":"87","author":"Rippon","year":"2022","journal-title":"J Alzheimers Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e70201","DOI":"10.1002\/alz.70201","article-title":"Global multi-specialty clinician perspectives on the implementation of Alzheimer\u2019s disease blood biomarkers.","volume":"21","author":"Rodda","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B122","doi-asserted-by":"publisher","first-page":"7808","DOI":"10.3390\/ijms25147808","article-title":"Establishing normal serum values of neurofilament light chains and glial fibrillary acidic protein considering the effects of age and other demographic factors in healthy adults.","volume":"25","author":"Rodero-Romero","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3233\/adr230007","article-title":"Current diagnostic pathways for Alzheimer\u2019s disease: A cross-sectional real-world study across six countries.","volume":"7","author":"Roth","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e2612793","DOI":"10.1001\/jamanetworkopen.2026.12793","article-title":"Glial fibrillary acidic protein and neurofilament light reference intervals in healthy individuals.","volume":"9","author":"Rousset","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"B125","doi-asserted-by":"publisher","first-page":"11941","DOI":"10.3390\/ijms252211941","article-title":"Neuroinflammatory biomarkers in Alzheimer\u2019s disease: From pathophysiology to clinical implications.","volume":"25","author":"Roveta","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B126","doi-asserted-by":"publisher","first-page":"e17123","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads.","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00415-025-12897-5","article-title":"Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer\u2019s disease diagnosis in a memory clinic cohort.","volume":"272","author":"Sarto","year":"2025","journal-title":"J. Neurol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"e70065","DOI":"10.1002\/trc2.70065","article-title":"Blood-based biomarker prescreening with different testing combinations and cutoffs: A simulation study examining efficacy and cost-effectiveness in Alzheimer\u2019s disease prevention studies.","volume":"11","author":"Sato","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B129","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1002\/alz.14346","article-title":"Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer\u2019s disease pathophysiology.","volume":"20","author":"Schauer","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease.","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/wnl.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis.","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"B132","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease.","volume":"5","author":"Sch\u00f6ll","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"B133","doi-asserted-by":"publisher","first-page":"100056","DOI":"10.1016\/j.tjpad.2024.100056","article-title":"Cutting through the noise: A narrative review of Alzheimer\u2019s disease plasma biomarkers for routine clinical use.","volume":"12","author":"Sch\u00f6ll","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B134","doi-asserted-by":"publisher","first-page":"e70080","DOI":"10.1002\/alz.70080","article-title":"Presynaptic loss and axonal degeneration synergistically correlate with longitudinal neurodegeneration and cognitive decline.","volume":"21","author":"Shi","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B135","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"B136","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40035-024-00439-4","article-title":"A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer\u2019s disease.","volume":"13","author":"Tagai","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"B137","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","article-title":"Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology.","volume":"102","author":"Therriault","year":"","journal-title":"EBioMedicine"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","article-title":"Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability.","volume":"4","author":"Therriault","year":"","journal-title":"Nat. Aging"},{"key":"B139","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study.","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2309403","DOI":"10.1080\/26941899.2024.2309403","article-title":"Mixture of regressions with multivariate responses for discovering subtypes in Alzheimer\u2019s biomarkers with detection limits.","volume":"3","author":"Tian","year":"2024","journal-title":"Data Sci. Sci."},{"key":"B141","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00401-011-0861-8","article-title":"Factors affecting A\u03b2 plasma levels and their utility as biomarkers in ADNI.","volume":"122","author":"Toledo","year":"2011","journal-title":"Acta Neuropathol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e14442","DOI":"10.1002\/alz.14442","article-title":"Plasma A\u03b2(42)\/A\u03b2(40) is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer\u2019s disease spectrum.","volume":"21","author":"Trelle","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B143","doi-asserted-by":"publisher","first-page":"e032134","DOI":"10.1161\/jaha.123.032134","article-title":"Plasma markers of Alzheimer\u2019s disease pathology, neuronal injury, and astrocytic activation and MRI load of vascular pathology and neurodegeneration: The SMART-MR study.","volume":"13","author":"Twait","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"B144","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.3390\/ijms24076518","article-title":"Inflammatory processes in Alzheimer\u2019s disease-pathomechanism, diagnosis and treatment: A review.","volume":"24","author":"Twarowski","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B145","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14283\/jpad.2021.70","article-title":"Blood derived amyloid biomarkers for Alzheimer\u2019s disease prevention.","volume":"9","author":"Udeh-Momoh","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B146","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3390\/diagnostics14212408","article-title":"Comparison of serum and cerebrospinal fluid neurofilament light chain concentrations measured by Ella\u2122 and Lumipulse\u2122 in patients with cognitive impairment.","volume":"14","author":"Urbano","year":"2024","journal-title":"Diagnostics"},{"key":"B147","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13195-026-02012-9","article-title":"Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer\u2019s disease using the Lumipulse platform.","volume":"18","author":"Valera-Barrero","year":"2026","journal-title":"Alzheimers Res. Ther."},{"key":"B148","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"e70014","DOI":"10.1002\/trc2.70014","article-title":"Understanding recent advances in non-amyloid\/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer\u2019s disease.","volume":"10","author":"Van Eldik","year":"2024","journal-title":"Alzheimers Dement ."},{"key":"B150","doi-asserted-by":"publisher","first-page":"e70752","DOI":"10.1002\/alz.70752","article-title":"Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer\u2019s disease biomarker measurement: Results and consensus of the Global biomarker standardization consortium.","volume":"21","author":"Verberk","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","article-title":"Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer\u2019s blood biomarkers (SABB) working group.","volume":"18","author":"Verberk","year":"2022","journal-title":"Alzheimers Dement."},{"key":"B152","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma amyloid as prescreener for the earliest Alzheimer pathological changes.","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann. Neurol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00415-023-12066-6","article-title":"Comparison of CSF and plasma NfL and pNfH for Alzheimer\u2019s disease diagnosis: A memory clinic study.","volume":"271","author":"Vrillon","year":"2024","journal-title":"J. Neurol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1554805","DOI":"10.3389\/fnagi.2025.1554805","article-title":"Assessing diagnostic performance of plasma biomarkers in Alzheimer\u2019s disease versus cognitively unimpaired individuals: P-tau217 emerges as the optimal marker in Chinese cohorts.","volume":"17","author":"Wang","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1660755","DOI":"10.3389\/fnagi.2025.1660755","article-title":"Validation of the robustness of blood-based biomarkers for predicting amyloid-\u03b2 positivity in Chinese populations.","volume":"17","author":"Wang","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"B156","doi-asserted-by":"publisher","first-page":"e198725","DOI":"10.1172\/jci198725","article-title":"Ruling in, ruling out: The clinical utility of plasma biomarkers in diagnosis of Alzheimer\u2019s disease.","volume":"135","author":"Wisch","year":"2025","journal-title":"J. Clin. Invest."},{"key":"B157","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13195-024-01630-5","article-title":"Analytical and clinical performance of eight Simoa(\u00ae) and Lumipulse(\u00ae) assays for automated measurement of plasma p-tau181 and p-tau217.","volume":"16","author":"Wojda\u0142a","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"B158","doi-asserted-by":"publisher","first-page":"e71048","DOI":"10.1002\/alz.71048","article-title":"APOE \u03b54 carriership determines a faster plasma p-tau217 progression in A\u03b2-positive individuals.","volume":"21","author":"Woo","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B159","doi-asserted-by":"publisher","first-page":"116901","DOI":"10.1016\/j.bios.2024.116901","article-title":"Sensitivity evaluation of an optical microfiber featuring interfaces with various gold nanoparticle morphologies: Application to the GFAP detection.","volume":"268","author":"Xiao","year":"2025","journal-title":"Biosens. Bioelectron."},{"key":"B160","doi-asserted-by":"publisher","first-page":"e70662","DOI":"10.1002\/alz.70662","article-title":"Donanemab in preclinical Alzheimer\u2019s disease: Screening and baseline data from TRAILBLAZER-ALZ 3.","volume":"21","author":"Yaari","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B161","doi-asserted-by":"publisher","first-page":"e70383","DOI":"10.1002\/dad2.70383","article-title":"Metabolic and renal factors associated with plasma phosphorylated tau analytes used to detect Alzheimer\u2019s disease pathology.","volume":"18","author":"Yang","year":"2026","journal-title":"Alzheimers Dement."},{"key":"B162","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1038\/s41598-017-09009-3","article-title":"Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases.","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e0295749","DOI":"10.1371\/journal.pone.0295749","article-title":"The associations between type 2 diabetes and plasma biomarkers of Alzheimer\u2019s disease in the health and aging brain study: Health disparities (HABS-HD).","volume":"19","author":"Yu","year":"2024","journal-title":"PLoS One"},{"key":"B164","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12961-025-01314-y","article-title":"A scoping review of national policies for dementia prevention and control in mainland China.","volume":"23","author":"Zhang","year":"2025","journal-title":"Health Res. Policy Syst."},{"key":"B165","doi-asserted-by":"publisher","first-page":"e14536","DOI":"10.1002\/alz.14536","article-title":"Plasma p-tau217 and p-tau217\/A\u03b21-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer\u2019s disease: Insights for research and clinical practice.","volume":"21","author":"Zhong","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B166","doi-asserted-by":"publisher","first-page":"41871","DOI":"10.1038\/s41598-025-25926-0","article-title":"Comparison of Simoa, high-sensitivity ELISA, and CLIA for serum neurofilament light chain quantification in multiple sclerosis.","volume":"15","author":"Zondra Revendova","year":"2025","journal-title":"Sci. Rep."},{"key":"B167","doi-asserted-by":"publisher","first-page":"102485","DOI":"10.1016\/j.arr.2024.102485","article-title":"CSF and blood glial fibrillary acidic protein for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis.","volume":"101","author":"Zou","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"B168","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s40520-026-03353-z","article-title":"Why acetylcholinesterase inhibitors should be considered disease-modifying drugs for Alzheimer\u2019s disease?","volume":"38","author":"Zuliani","year":"2026","journal-title":"Aging Clin. Exp. Res."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1852137\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:47:18Z","timestamp":1787302038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1852137\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":168,"alternative-id":["10.3389\/fnagi.2026.1852137"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1852137","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1852137"}}